Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05875870
Other study ID # 2023-04-003B
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 24, 2023
Est. completion date May 15, 2028

Study information

Verified date February 2024
Source Taipei Veterans General Hospital, Taiwan
Contact Hui-Mei Chen, PhD
Phone 886-2-28227101
Email alice@ntunhs.edu.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study plans to investigate the effectiveness of six-week light exposure combined with an exercise training program on improving sleep-wake rhythm, physical and mental symptoms, quality of life, one-year recurrence rate, and one-year survival rate of patients with lung and esophageal cancer.


Description:

This study plans to investigate the effectiveness of six-week light exposure combined with an exercise training program on improving sleep-wake rhythm, physical and mental symptoms, quality of life, one-year recurrence rate, and one-year survival rate of patients with lung and esophageal cancer. Two groups, parallel, randomly assigned clinical trials, long-term follow-up, repeated measurement (pre-test, 6th week, 12th week, 6th month, 12th month, five times in total), and a design of single center recruitment. The experimental group receiving an intervention comprised six weeks of light exposure combined with exercise training. The active control group receiving six weeks of stretching exercise. With a double-blind study design of participant blind and outcomes assessor blind, subjects were recruited from the thoracic surgery clinic and thoracic surgery ward of a medical center in northern Taiwan.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date May 15, 2028
Est. primary completion date May 15, 2028
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: 1. Patients with newly diagnosed primary lung cancer or esophageal cancer, from the first stage to the third stage. 2. At least 20 years of age. 3. Able to communicate in Mandarin Chinese or Taiwanese. 4. Literate and free from cognitive disabilities. 5. The attending physician agrees to participate in the study. 6. Those who can connect to the Internet with mobile devices such as computers, mobile phones, and tablets, or those whose family members can assist in the operation. 7. Those with Karnofsky Performance Scale (KPS) greater than or equal to 70 points. 8. Those who are hospitalized for lung cancer or esophageal cancer lesion resection. Exclusion Criteria: 1. Congestive heart failure. 2. Orthopedic diseases of the lower extremities that limit one's walking ability.

Study Design


Intervention

Behavioral:
Daylight exposure combine walking
Out-door of bright-light exposure in the morning (36 min/day, 7 times/week) for six weeks. Tailored to the individual patient with moderate intensity of walking (3 sessions/week) for six weeks. Duration of each session depends on one-on-one exercise consultation via communication software (LINE App). The duration of walking in week 1 is 15 minutes, then increasing 5 minutes each week if the patient has tolerance. If the patient cannot tolerate the duration, the coach will instruct to keep the same duration for the following week. Basically, the goal of duration in week six is 40 minutes. Weekly exercise consultation via communication software (LINE App). Teaching strategy includes one-on one instruction (hard-copy of teaching manual), video, and webpage.
Stretching exercise
The stretching exercise includes two movements for the upper body and two movements for the lower body, 10 minutes each time, three times a week, for 6 weeks. The researcher will explain to the participants about how to perform the stretching exercise, according to an instruction manual (hardcopy) for the exercise regimen. A video is shown to the participants (the content same as hardcopy of education manual).

Locations

Country Name City State
Taiwan Taipei Veterans General Hospital Taipei city Taipei

Sponsors (2)

Lead Sponsor Collaborator
Taipei Veterans General Hospital, Taiwan National Taipei University of Nursing and Health Sciences

Country where clinical trial is conducted

Taiwan, 

References & Publications (7)

Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, Zucker DS, Matthews CE, Ligibel JA, Gerber LH, Morris GS, Patel AV, Hue TF, Perna FM, Schmitz KH. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. doi: 10.1249/MSS.0000000000002116. — View Citation

Chen HM, Cheung DST, Lin YY, Wu YC, Liu CY, Lin KC, Lin YJ, Lin CC. Relationships of exercise timing with sleep, fatigue and rest-activity rhythms of lung cancer patients in Taiwan: An exploratory study. Eur J Cancer Care (Engl). 2020 Jul;29(4):e13233. do — View Citation

Chen HM, Lee MC, Tian JY, Dai MF, Wu YC, Huang CS, Hsu PK, Duong LT. Relationships Among Physical Activity, Daylight Exposure, and Rest-Activity Circadian Rhythm in Patients With Esophageal and Gastric Cancer: An Exploratory Study. Cancer Nurs. 2023 Jan 1 — View Citation

Chen HM, Lin YY, Wu YC, Huang CS, Hsu PK, Chien LI, Lin YJ, Huang HL. Effects of Rehabilitation Program on Quality of Life, Sleep, Rest-Activity Rhythms, Anxiety, and Depression of Patients With Esophageal Cancer: A Pilot Randomized Controlled Trial. Canc — View Citation

Chen HM, Tsai CM, Wu YC, Lin KC, Lin CC. Effect of walking on circadian rhythms and sleep quality of patients with lung cancer: a randomised controlled trial. Br J Cancer. 2016 Nov 22;115(11):1304-1312. doi: 10.1038/bjc.2016.356. Epub 2016 Nov 3. — View Citation

Chen HM, Tsai CM, Wu YC, Lin KC, Lin CC. Randomised controlled trial on the effectiveness of home-based walking exercise on anxiety, depression and cancer-related symptoms in patients with lung cancer. Br J Cancer. 2015 Feb 3;112(3):438-45. doi: 10.1038/b — View Citation

Chen HM, Wu YC, Tsai CM, Tzeng JI, Lin CC. Relationships of Circadian Rhythms and Physical Activity With Objective Sleep Parameters in Lung Cancer Patients. Cancer Nurs. 2015 May-Jun;38(3):215-23. doi: 10.1097/NCC.0000000000000163. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Sleep-wake rhythm Using Actigraph to measure sleep-wake rhythm. The parameter including 24-h correlation coefficient(r24), in bed less than out of bed dichotomy index (I < O), midline estimating statistic of rhythm (MESOR), and amplitude…etc. Baseline
Primary Sleep-wake rhythm Using Actigraph to measure sleep-wake rhythm. The parameter including 24-h correlation coefficient(r24), in bed less than out of bed dichotomy index (I < O), midline estimating statistic of rhythm (MESOR), and amplitude…etc. Change from baseline sleep-wake rhythm at 6th week
Primary Sleep-wake rhythm Using Actigraph to measure sleep-wake rhythm. The parameter including 24-h correlation coefficient(r24), in bed less than out of bed dichotomy index (I < O), midline estimating statistic of rhythm (MESOR), and amplitude…etc. Change from baseline sleep-wake rhythm at 12th week
Primary Sleep-wake rhythm Using Actigraph to measure sleep-wake rhythm. The parameter including 24-h correlation coefficient(r24), in bed less than out of bed dichotomy index (I < O), midline estimating statistic of rhythm (MESOR), and amplitude…etc. Change from baseline sleep-wake rhythm at 6th month
Primary Sleep-wake rhythm Using Actigraph to measure sleep-wake rhythm. The parameter including 24-h correlation coefficient(r24), in bed less than out of bed dichotomy index (I < O), midline estimating statistic of rhythm (MESOR), and amplitude…etc. Change from baseline sleep-wake rhythm at 12th month
Secondary Subjective sleep quality (Pittsburgh Sleep Quality Index, PSQI) The scale consists of 19 questions covering collective sleep quality, sleep latency, total sleep hours, sleep habits, sleep disturbance, use of sleeping drugs, and daytime functioning.
The PSQI score is calculated from the above seven facets. The score of each facet was 0-3 points, and the total score was 0-21 points. A score greater than 5 indicates that the total quality of sleep is poor.
Baseline
Secondary Subjective sleep quality (Pittsburgh Sleep Quality Index, PSQI) The scale consists of 19 questions covering collective sleep quality, sleep latency, total sleep hours, sleep habits, sleep disturbance, use of sleeping drugs, and daytime functioning.
The PSQI score is calculated from the above seven facets. The score of each facet was 0-3 points, and the total score was 0-21 points. A score greater than 5 indicates that the total quality of sleep is poor.
Change from baseline sleep-wake rhythm at 6th week
Secondary Subjective sleep quality (Pittsburgh Sleep Quality Index, PSQI) The scale consists of 19 questions covering collective sleep quality, sleep latency, total sleep hours, sleep habits, sleep disturbance, use of sleeping drugs, and daytime functioning.
The PSQI score is calculated from the above seven facets. The score of each facet was 0-3 points, and the total score was 0-21 points. A score greater than 5 indicates that the total quality of sleep is poor.
Change from baseline sleep-wake rhythm at 12th week
Secondary Subjective sleep quality (Pittsburgh Sleep Quality Index, PSQI) The scale consists of 19 questions covering collective sleep quality, sleep latency, total sleep hours, sleep habits, sleep disturbance, use of sleeping drugs, and daytime functioning.
The PSQI score is calculated from the above seven facets. The score of each facet was 0-3 points, and the total score was 0-21 points. A score greater than 5 indicates that the total quality of sleep is poor.
Change from baseline sleep-wake rhythm at 6th month
Secondary Subjective sleep quality (Pittsburgh Sleep Quality Index, PSQI) The scale consists of 19 questions covering collective sleep quality, sleep latency, total sleep hours, sleep habits, sleep disturbance, use of sleeping drugs, and daytime functioning.
The PSQI score is calculated from the above seven facets. The score of each facet was 0-3 points, and the total score was 0-21 points. A score greater than 5 indicates that the total quality of sleep is poor.
Change from baseline sleep-wake rhythm at 12th month
Secondary Objective sleep quality: total sleep time Using actigraph to measure total sleep time (min/night) Baseline
Secondary Objective sleep quality: total sleep time Using actigraph to measure total sleep time (min/night) Change from baseline total sleep time at 6th week
Secondary Objective sleep quality: total sleep time Using actigraph to measure total sleep time (min/night) Change from baseline total sleep time at 12th week
Secondary Objective sleep quality: total sleep time Using actigraph to measure total sleep time (min/night) Change from baseline total sleep time at 6th month
Secondary Objective sleep quality: total sleep time Using actigraph to measure total sleep time (min/night) Change from baseline total sleep time at 12th month
Secondary Objective sleep quality: sleep onset latency Using actigraph to measure sleep onset latency (min/night) Baseline
Secondary Objective sleep quality: sleep onset latency Using actigraph to measure sleep onset latency (min/night) Change from baseline sleep onset latency at 6th week
Secondary Objective sleep quality: sleep onset latency Using actigraph to measure sleep onset latency (min/night) Change from baseline sleep onset latency at 12th week
Secondary Objective sleep quality: sleep onset latency Using actigraph to measure sleep onset latency (min/night) Change from baseline sleep onset latency at 6th month
Secondary Objective sleep quality: sleep onset latency Using actigraph to measure sleep onset latency (min/night) Change from baseline sleep onset latency at 12th month
Secondary Objective sleep quality: sleep efficiency Using actigraph to measure sleep efficiency (percentage) Baseline
Secondary Objective sleep quality: sleep efficiency Using actigraph to measure sleep efficiency (percentage) Change from baseline sleep efficiency at 6th week
Secondary Objective sleep quality: sleep efficiency Using actigraph to measure sleep efficiency (percentage) Change from baseline sleep efficiency at 12th week
Secondary Objective sleep quality: sleep efficiency Using actigraph to measure sleep efficiency (percentage) Change from baseline sleep efficiency at 6th month
Secondary Objective sleep quality: sleep efficiency Using actigraph to measure sleep efficiency (percentage) Change from baseline sleep efficiency at 12th month
Secondary Objective sleep quality: wake after sleep onset Using actigraph to measure wake after sleep onset (min/night) Baseline
Secondary Objective sleep quality: wake after sleep onset Using actigraph to measure wake after sleep onset (min/night) Change from baseline wake after sleep onset at 6th week
Secondary Objective sleep quality: wake after sleep onset Using actigraph to measure wake after sleep onset (min/night) Change from baseline wake after sleep onset at 12th week
Secondary Objective sleep quality: wake after sleep onset Using actigraph to measure wake after sleep onset (min/night) Change from baseline wake after sleep onset at 6th month
Secondary Objective sleep quality: wake after sleep onset Using actigraph to measure wake after sleep onset (min/night) Change from baseline wake after sleep onset at 12th month
Secondary Anxiety and depression (Hospital Anxiety and Depression Scale, HADS) The scale consists of seven items each for anxiety and depression. Each item of the anxiety subscale (HADS-A) and the depression subscale (HADS-D) was scored on a 4-point scale from 0 (not at all) to 3 (very much so). Higher scores indicated higher anxiety or depression levels. Baseline
Secondary Anxiety and depression (Hospital Anxiety and Depression Scale, HADS) The scale consists of seven items each for anxiety and depression. Each item of the anxiety subscale (HADS-A) and the depression subscale (HADS-D) was scored on a 4-point scale from 0 (not at all) to 3 (very much so). Higher scores indicated higher anxiety or depression levels. Change from baseline anxiety and depression at 6th week
Secondary Anxiety and depression (Hospital Anxiety and Depression Scale, HADS) The scale consists of seven items each for anxiety and depression. Each item of the anxiety subscale (HADS-A) and the depression subscale (HADS-D) was scored on a 4-point scale from 0 (not at all) to 3 (very much so). Higher scores indicated higher anxiety or depression levels. Change from baseline anxiety and depression at 12th week
Secondary Anxiety and depression (Hospital Anxiety and Depression Scale, HADS) The scale consists of seven items each for anxiety and depression. Each item of the anxiety subscale (HADS-A) and the depression subscale (HADS-D) was scored on a 4-point scale from 0 (not at all) to 3 (very much so). Higher scores indicated higher anxiety or depression levels. Change from baseline anxiety and depression at 6th month
Secondary Anxiety and depression (Hospital Anxiety and Depression Scale, HADS) The scale consists of seven items each for anxiety and depression. Each item of the anxiety subscale (HADS-A) and the depression subscale (HADS-D) was scored on a 4-point scale from 0 (not at all) to 3 (very much so). Higher scores indicated higher anxiety or depression levels. Change from baseline anxiety and depression at 12th month
Secondary Quality of life (European Organization for Research and Treatment of cancer quality of life questionnaire) This questionnaire measures the general quality of life of cancer patients. There are 30 questions in total, including questions on physical functioning (5 questions), role function (2 questions), emotional functioning (4 questions),and cognitive functioning (2 questions), as well as, overall quality of life and health status (2 questions). And common symptoms such as fatigue (3 questions), pain (2 questions), nausea and vomiting (2 questions), dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial problems (one question each). Baseline
Secondary Quality of life (European Organization for Research and Treatment of cancer quality of life questionnaire) This questionnaire measures the general quality of life of cancer patients. There are 30 questions in total, including questions on physical functioning (5 questions), role function (2 questions), emotional functioning (4 questions),and cognitive functioning (2 questions), as well as, overall quality of life and health status (2 questions). And common symptoms such as fatigue (3 questions), pain (2 questions), nausea and vomiting (2 questions), dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial problems (one question each). Change from baseline quality of life at 6th week
Secondary Quality of life (European Organization for Research and Treatment of cancer quality of life questionnaire) This questionnaire measures the general quality of life of cancer patients. There are 30 questions in total, including questions on physical functioning (5 questions), role function (2 questions), emotional functioning (4 questions),and cognitive functioning (2 questions), as well as, overall quality of life and health status (2 questions). And common symptoms such as fatigue (3 questions), pain (2 questions), nausea and vomiting (2 questions), dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial problems (one question each). Change from baseline quality of life at 12th week
Secondary Quality of life (European Organization for Research and Treatment of cancer quality of life questionnaire) This questionnaire measures the general quality of life of cancer patients. There are 30 questions in total, including questions on physical functioning (5 questions), role function (2 questions), emotional functioning (4 questions),and cognitive functioning (2 questions), as well as, overall quality of life and health status (2 questions). And common symptoms such as fatigue (3 questions), pain (2 questions), nausea and vomiting (2 questions), dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial problems (one question each). Change from baseline quality of life at 6th month
Secondary Quality of life (European Organization for Research and Treatment of cancer quality of life questionnaire) This questionnaire measures the general quality of life of cancer patients. There are 30 questions in total, including questions on physical functioning (5 questions), role function (2 questions), emotional functioning (4 questions),and cognitive functioning (2 questions), as well as, overall quality of life and health status (2 questions). And common symptoms such as fatigue (3 questions), pain (2 questions), nausea and vomiting (2 questions), dyspnea, insomnia, loss of appetite, constipation, diarrhea, and financial problems (one question each). Change from baseline quality of life at 12th month
Secondary Recurrent rate Chart review to determine whether cancer has recurred for participant one year after diagnosis. 12th month after recruitment
Secondary Survival rate Chart review to determine whether participant survived one year after diagnosis. 12th month after recruitment
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05013697 - TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer. Phase 2
Completed NCT02128243 - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Phase 2
Completed NCT02253602 - Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer N/A
Completed NCT01900691 - Removal of the Evolution® Esophageal Stent - Fully Covered N/A
Completed NCT01719926 - Phase I Platinum Based Chemotherapy Plus Indomethacin Phase 1
Terminated NCT01572987 - Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus N/A
Terminated NCT00760604 - A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer Phase 3
Completed NCT00160030 - Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer Phase 2
Suspended NCT00048529 - Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Completed NCT02284802 - Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy N/A
Terminated NCT03223662 - Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy Phase 2
Completed NCT05680077 - KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT03261947 - A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Phase 2
Terminated NCT00094978 - Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum Phase 1
Recruiting NCT02908204 - Long-term Outcomes of Superficial Esophageal Squamous Cell Carcinoma N/A
Completed NCT02703142 - Endoscopic Evaluation After Esophagectomy N/A
Completed NCT02378948 - Nutritional Route In Esophageal Resection Trial II N/A
Recruiting NCT02604615 - The Role of Different Cycles of Chemotherapy(Capecitabine-oxaliplatin) in Esophageal Chemoradiotherapy Phase 3